Article

FDA extends aflibercept review

The FDA has extended by 3 months its target date to complete a priority review of the biologics license application (BLA) of aflibercept injection for intravitreal use (Eylea, also known as VEGF Trap-Eye, Regeneron Pharmaceuticals) for the treatment of neovascular age-related macular degeneration (AMD) to Nov. 18.

Tarrytown, NY-The FDA has extended by 3 months its target date to complete a priority review of the biologics license application (BLA) of aflibercept injection for intravitreal use (Eylea, also known as VEGF Trap-Eye, Regeneron Pharmaceuticals) for the treatment of neovascular age-related macular degeneration (AMD) to Nov. 18.

The agency classified recent responses to questions regarding the chemistry, manufacturing, and controls section of the BLA as a major amendment to the application, according to the company. The new action date will give the agency additional time to review the submitted information.

Regeneron maintains exclusive rights to aflibercept injection in the United States, but the company is collaborating with Bayer HealthCare on the global development of the fusion protein for the treatment of neovascular AMD, central retinal vein occlusion, diabetic macular edema, and other eye diseases and disorders.

Bayer HealthCare will market aflibercept injection outside the United States, where the companies will share equally in the profits from any future sales of the fusion protein. In June, Bayer submitted an application to market the product for wet AMD in Europe.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.